Boston, Massachusetts 2021-07-19 11:40:17 –
ADutch ntitrust regulators have given pharmaceutical companies 23 million in response to “excessive” price increases for rare disease drugs, the latest case in which European authorities cracked down on the pharmaceutical industry for harming consumers and taxpayers. I fined the dollar.
In this case, the Dutch Consumer Markets Authority quoted Leadiant for a complex set of operations whose prices rose from $ 54 in early 2009 to over $ 16,000 by 2017 (see details). Here). Soaring costs have caused what the agency has called a “public protest” until major medical centers in Amsterdam finally make their own cheaper versions available in 2020.
Dutch authorities fine drug maker $23 million over rare disease drug pricing Source link Dutch authorities fine drug maker $23 million over rare disease drug pricing